Evidence map›Paper›PMID 31758430›Full record

ArticleDigestive diseases and sciences2020

Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit.

Henry P Parkman, Emily P Sharkey, Linda A Nguyen, Katherine P Yates, Thomas L Abell, William L Hasler, William Snape, John Clarke, Ron Schey, Kenneth L Koch and 8 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01696747 (GpR 2), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01696747 completednot on this map

GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan2012 to 2019Enrolled506ConditionsGastroparesis, Diabetic Gastroparesis, Idiopathic Gastroparesis
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
    Trial
  2. Article
  3. Article
  4. Review
  5. Pharmacologic treatments for gastroparesis.Pharmacological reviews · 2025
    Review
  6. Article
  7. Article
  8. Cannabinoids and the Gastrointestinal Tract.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
    Review
  9. Review
  10. Gastroparesis.Gastroenterology · 2022
    Review
  11. Management of Gastroparesis.Gastroenterology & hepatology · 2021
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Henry P ParkmanNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA. henry.parkman@temple.edu.ORCID 0000-0003-4904-4891
Emily P SharkeyNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Linda A NguyenNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Katherine P YatesNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Thomas L AbellNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
William L HaslerNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
William SnapeNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
John ClarkeNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Ron ScheyNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Kenneth L KochNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Braden KuoNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Richard W McCallumNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Irene SarosiekNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Madhusudan GroverNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Gianrico FarrugiaNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
James TonasciaNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Pankaj J PasrichaNIH Gastroparesis Clinical Research Consortium, Bethesda, MD, USA.
Frank A. Hamilton for the NIH Gastroparesis Consortium
Clinical Research Consortium · US

Funding

Gastroparesis Consortium Continuation-Data Coordinating CenterU01DK074008 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 2006 to 2015
$17.4M
PGpR2 Year 4 Supplement for the Scientific Data Research Center (SDRC) of the GpCRC 4U24DK074008 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI David M Shade · 2017 to 2026
$11.7M
Subtypes of GastroparesisU01DK073974 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Baharak Moshiree · 2006 to 2026
$7.4M
Temple University Gastroparesis Clinical CenterU01DK073975 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI HENRY PAUL PARKMAN · 2006 to 2026
$7.4M
U of L Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis ConsortiumU01DK074007 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI Thomas Lyman Abell · 2006 to 2026
$7.0M
Molecular Approaches to Pathogenesis/Therapy in GastropaU01DK073983 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI PANKAJ J PASRICHA · 2006 to 2026
$6.8M
The GpCRC Pediatric Gastroparesis Registry 2 (PGpR2): Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric, Adolescent, and Young Adult Participants with Symptoms of GastU01DK074035 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Irene Sarosiek · 2008 to 2026
$6.7M
New England Gastropareis Consortium: Neurobiology of GastroparesisU01DK112193 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Helen Burton Murray, Braden Kuo · 2016 to 2026
$4.8M
NIDDK NIH HHS U01 DK073974NIDDK NIH HHS U01 DK073975NIDDK NIH HHS U01 DK073983NIDDK NIH HHS U01 DK074007NIDDK NIH HHS U01 DK074008NIDDK NIH HHS U01 DK074035NIDDK NIH HHS U01 DK112193NIDDK NIH HHS U24 DK074008
6 · The paper itself

Abstract

backgroundMarijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects.

aimsThe aim of this study was to describe the use of marijuana by patients for symptoms of Gp, assessing prevalence of use, patient characteristics, and patients' perceived benefit on their symptoms of Gp.

methodsPatients with symptoms of Gp underwent history and physical examination, gastric emptying scintigraphy, and questionnaires assessing symptoms. Patients were asked about the current use of medications and alternative medications including marijuana.

resultsFifty-nine of 506 (11.7%) patients with symptoms of Gp reported current marijuana use, being similar among patients with delayed and normal gastric emptying and similar in idiopathic and diabetic patients. Patients using marijuana were younger, more often current tobacco smokers, less likely to be a college graduate, married or have income > $50,000. Patients using marijuana had higher nausea/vomiting subscore (2.7 vs 2.1; p = 0.002), higher upper abdominal pain subscore (3.5 vs 2.9; p = 0.003), more likely to be using promethazine (37 vs 25%; p = 0.05) and dronabinol (17 vs 3%; p < 0.0001). Of patients using marijuana, 51% had been using it for more than 2 years, 47% were using this once or more per day, and 81% of marijuana users rated their benefit from marijuana as better or much better.

conclusionsA subset of patients (12%) with symptoms of Gp use marijuana. Patients with severe nausea and abdominal pain were more likely to use marijuana and perceive it to be beneficial for their symptoms.

trial registrationClinicalTrials.gov Identifier: NCT01696747.

Indexed as

Marijuana UseAdultCohort StudiesFemaleGastroparesisHumansMaleMiddle AgedYoung AdultCannabinoidsCannabisDronabinolGastroparesisMarijuana

Identifiers

PMID31758430
PMCPMC7242137
OpenAlexW2989985595

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.